Investors can expect a company’s stock to rise or fall based on the buying and selling of stock by its insiders. Recursion Pharmaceuticals Inc shares valued at $959,200 were sold by Borgeson Blake on Jan 06 ’26. At $4.36 per share, Borgeson Blake sold 220,000 shares. The insider’s holdings dropped to 6,649,863 shares worth approximately $32.25 million following the completion of this transaction.
Also, Gibson Christopher sold 40,000 shares, netting a total of over 170,000 in proceeds. Following the sale of shares at $4.25 each, the insider now holds 933,839 shares.
Before that, Borgeson Blake had added 220,000 shares to its account. In a trade valued at $959,200, the Director bought Recursion Pharmaceuticals Inc shares for $4.36 each.
As published in a research note from JP Morgan on December 17, 2025, Recursion Pharmaceuticals Inc [RXRX] has been rated up from a Neutral to an Overweight and the price target has been revised to $11. As of May 22, 2023, Morgan Stanley has initiated its “an Equal-weight” rating for RXRX. Earlier on March 16, 2023, Needham initiated its rating. Their recommendation was “a Buy” for RXRX stock.
Analyzing RXRX Stock Performance
On last trading session, Recursion Pharmaceuticals Inc [NASDAQ: RXRX] rose 3.41% to $4.85. The stock’s lowest price that day was $4.61, but it reached a high of $4.87 in the same session. During the last five days, there has been a drop of approximately -0.21%. Over the course of the year, Recursion Pharmaceuticals Inc shares have dropped approximately -28.04%.
Is Recursion Pharmaceuticals Inc subject to short interest?
Stocks of Recursion Pharmaceuticals Inc saw a sharp rise in short interest on 2025-12-31 jumping by 13.86 million shares to 165.73 million. Data from Yahoo Finance shows that the short interest on 2025-11-28 was 151.88 million shares. A jump of 8.36% in short interest reflects a negative sentiment towards the stock. Despite the fact that short shares comprise just 7.18 of the overall float, the days-to-cover ratio (short ratio) jumped to 7.18.
Which companies own the most shares of Recursion Pharmaceuticals Inc (RXRX)?
In terms of Recursion Pharmaceuticals Inc share price expectations, FactSet research, analysts set an average price target of 11 in the next 12 months, up nearly 134.54% from the previous closing price of $4.69. Analysts anticipate Recursion Pharmaceuticals Inc stock to reach 11 by 2026, with the lowest price target being 11. In spite of this, 3 analysts ranked Recursion Pharmaceuticals Inc stock as Buy at the end of 2026. On September 16, 2022, KeyBanc Capital Markets assigned a price target of “an Overweight” to the stock and initiated coverage with a $20.
